financetom
Business
financetom
/
Business
/
Nike's new CEO plans to go back to basics in brand overhaul effort
News World Market Environment Technology Personal Finance Politics Retail Business Economy Cryptocurrency Forex Stocks Market Commodities
Nike's new CEO plans to go back to basics in brand overhaul effort
Dec 20, 2024 3:04 AM

(Reuters) - Nike's ( NKE ) new CEO Elliott Hill warned of a long road to sales recovery for the sportswear giant, but the veteran executive's plan to turn the spotlight on sports like basketball and running, allayed some investor worries.

The company said on Thursday it was expecting third-quarter revenue to drop to low double digits after the embattled sportswear seller's quarterly results beat market estimates.

Hill, in his first public address as CEO on the post-earnings call, said Nike ( NKE ) had "lost its obsession with sport" and vowed to put it back on track by refocusing on sport and selling more items at premium prices.

"The recovery is going to be a multi-year process, but he(Hill) seems to be going back to the roots, back to Nike ( NKE ) being Nike ( NKE )," said John Nagle, chief investment officer at Kavar Capital Partners, which owns Nike ( NKE ) shares.

"(Hill plans to shift focus) away from some of the streetwear and fashion that had taken over the brand, the heavy discounting and the neglect of retailers. Just taking it back to what worked," Nagle said.

Hill, who was with Nike ( NKE ) for more than three decades, returned as CEO in October to revive demand at the firm that has been struggling with strategy missteps that soured its relations with retailers such as Foot Locker ( FL ).

The company also saw its market share dwindle as rival brands, including Roger Federer-backed On and Deckers' Hoka, lured consumers with fresher and more innovative styles.

Hill also highlighted that a lack of newness led Nike ( NKE ) to become too promotional and said he plans to shift to selling more at full price on its website and app.

Shares of Nike ( NKE ), which have lost about half of its value in the last three years, were down about 4% in premarket hours on the muted forecast as some analysts expect short-term margin pressure.

"With another half year of franchise management coupled with investment to reinvigorate the brand, we believe the next four quarters could be the worst of the margin erosion and EPS reductions," Barclays analyst Adrienne Yih said.

Nike's ( NKE ) forward price-to-earnings ratio for the next 12 months, a benchmark for valuing stocks, was 27.53, compared with 33.47 for Deckers and 32.32 for Adidas.

"A rudderless ship now has a rudder, and a sailor who knows how to drive it," said Eric Clark, portfolio manager at the Rational Dynamic Brands fund, which owns Nike ( NKE ) shares.

(Reporting by Aishwarya Venugopal in Bengaluru; Editing by Arun Koyyur)

Comments
Welcome to financetom comments! Please keep conversations courteous and on-topic. To fosterproductive and respectful conversations, you may see comments from our Community Managers.
Sign up to post
Sort by
Show More Comments
Related Articles >
Hotel101 To Go Public With JVSPAC Merger: Details
Hotel101 To Go Public With JVSPAC Merger: Details
Apr 8, 2024
Blank check company JVSPAC Acquisition Corporation ( JVSA ) has entered into a merger agreement with the Singapore-headquartered subsidiary of Philippine-listed investment company DoubleDragon Corporation, Hotel101 Global Pte. Ltd. and affiliates. Hotel101 is a hotel prop-tech operator that specializes in asset-light “condotel” business models. Upon the merger completion, the combined entity is expected to be publicly listed on the NASDAQ under the ticker...
US FDA allows J&J, Bristol Myers cell therapies as early cancer treatments (April 5)
US FDA allows J&J, Bristol Myers cell therapies as early cancer treatments (April 5)
Apr 8, 2024
By Sneha S K and Bhanvi Satija April 5 (Reuters) - The U.S. Food and Drug Administration has allowed the cell therapies of Johnson & Johnson and Bristol Myers Squibb to be used as earlier lines of treatments in patients with a type of blood cancer, the companies said on Friday. Both J&J and Bristol Myers' therapies helped extend the...
Black Diamond Therapeutics Says BDTX-1535 Potentially Inhibits Non-Classical Mutations in Non-Small Cell Lung Cancer Patients
Black Diamond Therapeutics Says BDTX-1535 Potentially Inhibits Non-Classical Mutations in Non-Small Cell Lung Cancer Patients
Apr 8, 2024
05:50 AM EDT, 04/08/2024 (MT Newswires) -- Black Diamond Therapeutics ( BDTX ) said Sunday that preclinical data showed that BDTX-1535 potentially inhibits non-classical mutations in non-small cell lung cancer patients. Real-world data showed non-classical mutations were present in 20% to 30% of subject patients with non-small cell lung cancer, and that BDTX-1535 has the potential to address a broader...
Update: Meta Contests FTC's Bid to Amend 2020 Privacy Settlement on Messenger Kids
Update: Meta Contests FTC's Bid to Amend 2020 Privacy Settlement on Messenger Kids
Apr 8, 2024
05:52 AM EDT, 04/08/2024 (MT Newswires) -- (Updates with response from the US Federal Trade Commission in the fourth paragraph.) Meta (META) pushed back on the US Federal Trade Commission's bid to amend a 2020 privacy settlement concerning the company's child-friendly chat, Messenger Kids, saying it had voluntarily disclosed two technical errors in the application to the agency. The company...
Copyright 2023-2026 - www.financetom.com All Rights Reserved